P.O. Box 134
Malvern, PA 19355
United States
610 725 1500
https://www.galeratx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. J. Mel Sorensen M.D. | CEO, President & Director | 632.64k | N/D | 1957 |
Dr. Robert A. Beardsley M.B.A., Ph.D. | Co-Founder & COO | 464.59k | N/D | 1962 |
Mr. Christopher Degnan | Chief Financial Officer | 474.05k | N/D | 1980 |
Ms. Jennifer Evans Stacey Esq. | Chief Legal & Compliance Officer and Secretary | N/D | N/D | 1965 |
Ms. Andie Collier | Chief Regulatory & Quality Affairs Officer | N/D | N/D | N/D |
Ms. Judy Schnyder | Senior Vice President of Clinical Operations & Data Management | N/D | N/D | N/D |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
La calificación ISS Governance QuickScore de Galera Therapeutics, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 7; Compensación: 8.